The New England journal of medicine
-
The Pfizer–BioNTech COVID-19 vaccine was 91% effective in preventing infection with SARS-CoV-2 in phase 3 trials.
pearl
The Pfizer–BioNTech COVID-19 vaccine was 91% effective in preventing infection with SARS-CoV-2 in phase 3 trials.
pearl